Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meropenem versus piperacillin-tazobactam for ceftriaxone-resistant E. coli or Klebsiella bloodstream infection
ACTRN12615000403538Phase 4Terminated
- Sponsor
- ASID Clinical Research Network
- Start
- Apr 2015
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 4, randomised, open-label trial in Escherichia coli bacteremia and Klebsiella bloodstream infection (KBSI) comparing Piperacillin-tazobactam with Meropenem (2 arms). Primary endpoint: 30-day mortality. Started Apr 2015; status: terminated.
02
Drugs
meropenempiperacillin + tazobactam
03
Conditions
Escherichia coli bacteremiaKlebsiella bloodstream infection (KBSI)
Beyond the preview
Go deeper on ACTRN12615000403538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000403538.